Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.48 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11581797 | 0.79 | KMT2A (0.52) | GRM5MEN1KMT2AMAPK10GFER | |
| SCHEMBL11718975 | 0.79 | MEN1 (0.47) | GRM5MEN1KMT2AMAPK10GFER | |
| SCHEMBL4943709 | 0.78 | MEN1 (0.73) | MEN1KMT2AMAPK10GFERNPC1 | |
| SCHEMBL19851118 | 0.78 | CA12 (0.63) | MEN1KMT2AGFERCA12CA1 | |
| SCHEMBL1859867 | 0.78 | CA12 (0.63) | MEN1KMT2AGFERCA12CA1 | |
| SCHEMBL11555781 | 0.78 | GRM5 (0.66) | GRM5MEN1KMT2ACA12CA1 | |
| SCHEMBL2501726 | 0.77 | KMT2A (0.70) | GRM5MEN1KMT2AMAPK10GFER | |
| SCHEMBL23319547 | 0.77 | GRM5 (0.54) | GRM5MEN1KMT2AMAPK10GFER | |
| SCHEMBL5772959 | 0.77 | GRM5 (0.58) | GRM5MEN1KMT2AMAPK10GFER | |
| SCHEMBL4242193 | 0.77 | CA12 (0.49) | MEN1KMT2AMAPK10CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4195088-A | ANTISECRETORY AGENTS, ANTIULCER AGENTS, ANOREXIGENIC AGENTS | ROUSSEL UCLAF (FR) | 1980-03-25 | — | — | US | claimed |
| EP-0006931-A1 | NEW SUBSTITUTED BY-PRODUCTS OF 1,3-DIHYDRO IMIDAZO (4,5-b) PYRIDIN-2-ONE, PROCESS, APPLICATION, COMPOSITIONS AND INTERMEDIATE COMPOUNDS OBTAINED | ROUSSEL-UCLAF (FR) | 1980-01-23 | — | — | EP | claimed |
| WO-1979000206-A1 | NEW SUBSTITUTED BY-PRODUCTS OF 1,3-DIHYDRO IMIDAZO(4,5-B)PYRIDIN-2-ONE,PROCESS,APPLICATION,COMPOSITIONS AND INTERMEDIATE COMPOUNDS OBTAINED | ROUSSEL UCLAF (FR) | 1979-04-19 | — | — | WO | claimed |
| US-8653089-B2 | Heterocyclic compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2014-02-18 | — | — | US | disclosed |
| US-8653089-B2 | Heterocyclic compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2014-02-18 | — | — | US | disclosed |
| WO-2012107465-A1 | HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-16 | — | — | WO | disclosed |
| US-20120202785-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-09 | — | — | US | disclosed |
| US-20120202785-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-09 | — | — | US | disclosed |
| US-6727245-B2 | 4-(HETERO)ARYL-3-OXO-3,4-DIHYDROPYRIDO(2,3-B)PYRAZINE DERIVATIVES; PROPHYLACTIC OR THERAPEUTIC TREATMENT OF PHOSPHODIESTERASE IV AND TUMOR NECROSIS FACTOR MEDIATED DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-04-27 | — | — | US | disclosed |
| EP-0770079-B1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2003-02-12 | — | — | EP | disclosed |
| US-20020107251-A1 | Heterobicyclic derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-08-08 | — | — | US | disclosed |
| CN-1250776-A | Heterodicyclic compound derivatives | FUJISAWA PHARMACEUTICAL CO (JP) | 2000-04-19 | — | — | CN | disclosed |
| CN-1051548-C | Heterobicyclic derivatives, pharmaceutical compositions containing them, process for preparing them and their use | FUJISAWA PHARMACEUTICAL CO (JP) | 2000-04-19 | — | — | CN | disclosed |
| EP-0920867-A1 | Pyrido[2,3-a]pyrazine derivatives as PDE-IV and TNF inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-06-09 | — | — | EP | disclosed |
| CN-1157617-A | Heterobicyclic derivatives | FUJISAWA PHARMACEUTICAL CO (JP) | 1997-08-20 | — | — | CN | disclosed |
| EP-0770079-A1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-05-02 | — | — | EP | disclosed |
| WO-1996001825-A1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-01-25 | — | — | WO | disclosed |
| US-4195088-A | ANTISECRETORY AGENTS, ANTIULCER AGENTS, ANOREXIGENIC AGENTS | ROUSSEL UCLAF (FR) | 1980-03-25 | — | — | US | disclosed |
| EP-0006931-A1 | NEW SUBSTITUTED BY-PRODUCTS OF 1,3-DIHYDRO IMIDAZO (4,5-b) PYRIDIN-2-ONE, PROCESS, APPLICATION, COMPOSITIONS AND INTERMEDIATE COMPOUNDS OBTAINED | ROUSSEL-UCLAF (FR) | 1980-01-23 | — | — | EP | disclosed |
| WO-1979000206-A1 | NEW SUBSTITUTED BY-PRODUCTS OF 1,3-DIHYDRO IMIDAZO(4,5-B)PYRIDIN-2-ONE,PROCESS,APPLICATION,COMPOSITIONS AND INTERMEDIATE COMPOUNDS OBTAINED | ROUSSEL UCLAF (FR) | 1979-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202785-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, AKT3 | GRM5 2735/4885MEN1 2411/4885KMT2A 4182/4885 |
| US-20020107251-A1 | Heterobicyclic derivatives | ARSA, ARRB1, SULT2A1 | GRM5 2614/4885MEN1 2703/4885KMT2A 968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.